2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 601–700 of 2,029
Makgopa, H. M., Kemp, T., Meldau, S., et al. (2024) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v13i1.2384 · Cited by 3
Point‐of‐care diabetes testing in the dental setting: A national scope of practice survey
Laniado, N., Brodigan, A. E., & Cloidt, M. (2024) · Journal of Public Health Dentistry · doi:10.1111/jphd.12631 · Cited by 3
Kim, H. J., Hur, K. Y., Lee, Y., Kim, J. T., Lee, Y.-K., Baek, K., Choi, E. J., Hwang, W. M., Bang, K. T., Lim, J. S., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02862-5 · Cited by 4
Cytochrome P450-soluble epoxide hydrolase oxylipins, depression and cognition in type 2 diabetes
Anita, N. Z., Herrmann, N., Ryoo, S. W., Major-Orfao, C., Lin, W. Z., Kwan, F., Noor, S., Rabin, J. S., Marzolini, S., Nestor, S. M., et al. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108826 · Cited by 5
Remission of type 2 diabetes mellitus: Emerging concepts and proposed diagnostic criteria
Raveendran, A. V. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i4.95210 · Cited by 5
Yi, X., Pan, Y., Huan, P., Ren, M., Jia, Q., & Wang, B. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108846 · Cited by 3
Fukui, H., Onishi, H., Ota, T., et al. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.08.007 · Cited by 3
Quansah, D. Y., Visintini, S. M., O’Neill, C. D., Savard, K., Lewis, R., Coutinho, T. A., & Mullen, K. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084212 · Cited by 3
Vásquez-Tirado, G., Guarniz-Salavarria, J. D., Quispe-Castañeda, C., Contreras-Cabrera, J. M., Cuadra-Campos, M., Meregildo-Rodríguez, E., Segura-Plasencia, N., & Arbayza-Ávalos, Y. K. (2024) · Endocrine · doi:10.1007/s12020-024-04019-4 · Cited by 2
“[14].”
Chen, Y., Xian, H., Liu, M., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1490831 · Cited by 3
Zhao, H., Yin, R., Wang, Y., Wang, Z., Zhang, L., Xu, Y., Wang, D., Wu, J., Wei, L., Yang, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-77996-1 · Cited by 6
“Diabetes were defined as follows, (1) previously diagnosed with diabetes by a medical expert, (2) FBG ≥ 7.0 mmol/L, (3) HbA1c > 6.5%, or (4) taking diabetes medication 20 .”
MethodInfluentialTsiakas, S., Angelousi, A. G., Benetou, V., Orfanos, P., Xagas, E., Boletis, J., & Marinaki, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226712 · Cited by 5
“The American Diabetes Association criteria or the initiation of anti-diabetic treatment after transplantation was used for the diagnosis of PTDM [37].”
Juza, A., Kołodziej-Spirodek, L., Gutkowski, K., Partyka, M., & Dąbrowski, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.95102 · Cited by 4
Takada, K., Yoshioka, Y., Morikawa, K., Ariyoshi, W., & Yamasaki, R. (2025) · Antibiotics · doi:10.3390/antibiotics14010036 · Cited by 4
Seyithanoğlu, M., Meşen, S., Çömez, A., Meşen, A., Beyoğlu, A., Baykişi, Y., & Baylan, F. A. (2025) · PeerJ · doi:10.7717/peerj.18841 · Cited by 4
“The patient group consisted of individuals diagnosed with type 2 diabetes mellitus (T2DM) based on the 2024 American Diabetes Association (ADA) diagnostic criteria ( American Diabetes Association Professional Practice Committee, 2024 ).”
Klasik-Ciszewska, S. B., Londzin, P., Grzywnowicz, K., Borymska, W., Zych, M., Kaczmarczyk-Żebrowska, I., & Folwarczna, J. (2025) · Nutrients · doi:10.3390/nu17020316 · Cited by 4
Rashad, B. H., Hussein, N. R., Dirbas, V. H., & Naqid, I. A. (2025) · Cureus · doi:10.7759/cureus.77618 · Cited by 3
Co-existing autonomous cortisol secretion in primary aldosteronism
Barlas, T., Altınova, A. E., Törüner, F. B., Cerit, E. T., Yalçın, M. M., Karakoç, M. A., & Aktürk, M. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101706 · Cited by 3
Saxena, I., Kumar, M., Kannoujia, B. L., Aishwarya, R., & Sen, A. (2025) · Cureus · doi:10.7759/cureus.78842 · Cited by 3
Immature Platelet Fraction and Other Platelet Indices in Type 2 Diabetes Mellitus
Siddiqui, N. A., Narang, S., Aggarwal, A., et al. (2025) · Cureus · doi:10.7759/cureus.79093 · Cited by 3
Ku, K.-C., Zhong, J., Song, E., Fong, C. H.-Y., Lam, K. S. L., Xu, A., Lee, C., & Cheung, C. Y. Y. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.102867 · Cited by 3
Lin, T.-C., Lacorcia, M., & Mannering, S. I. (2025) · Biomolecules · doi:10.3390/biom15030384 · Cited by 5
“T1D is most frequently diagnosed at stage 3 T1D [11,13].”
Risi, R., Amendolara, R., Balena, A., Watanabe, M., Masi, D., Fassino, V., Luverà, D., D’Onofrio, L., Lauria, A., Zampetti, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112114 · Cited by 3
Salmen, B.-M., Reurean‐Pintilei, D., Trofin, D., Durdu, C.-E., Neagu, A., & Bohîlțea, R. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073022 · Cited by 4
“The diagnosis is made after excluding other types of DM such as pre-existing overt DM, type 1 DM (T1DM), or other forms of DM that could complicate pregnancy [1].”
Electrocardiographic Changes in Patients with Type 2 Diabetes Mellitus—A Meta-Analysis
Alexescu, T., Nechita, A., Alexander, P. C., Perné, M.-G., Milaciu, M. V., Ciulei, G., Para, I., Negrean, V., Chiș, A. F., Todea, D. A., et al. (2025) · Journal of Mind and Medical Sciences · doi:10.3390/jmms12010014 · Cited by 3
Govindaraju, D., Subbian, S., & Narayanan, S. N. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108799 · Cited by 3
Yang, L., Li, J., Xie, Y., & Qian, G. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03873-4 · Cited by 7
He, W. J., Geng, S., Tian, L., & Hu, F. B. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101744 · Cited by 7
Association between weight loss and HbA1c management in patients with diabetes: a NHANES analysis
Zhang, Z., Gu, P., Li, G., & Du, W. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00440-x · Cited by 6
Yang, B., Yang, T., Hou, C., Li, Y., & Wang, Q. (2025) · Virology Journal · doi:10.1186/s12985-025-02703-z · Cited by 5
“The screening criteria for type 2 diabetes (T2DM), hypertension, and obesity were based on their respective diagnostic standards [20–22].”
Kaewkrasaesin, C., Hwang, M., Vasandani, C., Brown, R. J., & Garg, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf315 · Cited by 5
Matsuda, T., Osaki, Y., Soma, N., Azuma, T., Ezura, A., Mitani, Y., Kikuchi, Y., Matsumoto, N., Murayama, Y., Sugano, Y., et al. (2025) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2024-0083 · Cited by 4
Zhang, Y., Li, W.-Y., & Wan, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1586309 · Cited by 3
Meng, J., Lu, Y., Gao, X., Hao, J., Li, X., Ning, X., Zhang, W., & Wang, J. (2025) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s522995 · Cited by 6
“27 1 showed that a total of 2869 low-income, low-education middle-aged, and elderly individuals were initially enrolled.”
Eilertsen, R. K., Midtbø, H. B., Nawaz, B., Fromm, A., Waje‐Andreassen, U., & Gerdts, E. (2025) · Blood Pressure · doi:10.1080/08037051.2025.2521523 · Cited by 4
“Diabetes mellitus was considered present if fasting blood glucose was ≥ 7 mmol/L, HbA 1c was ≥ 6.5% [17], or if use of glucose lowering drugs was reported in the individual participant.”
InfluentialPan, W., Cai, S., Huang, Z., & Yu, K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1510210 · Cited by 3
Immune checkpoint inhibitor-associated diabetes mellitus: the case series report
Ma, Y., Xue, J., Cheng, Q., Qian, H., & Du, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1589630 · Cited by 3
Endocannabinoid and AGE Interactions in Prediabetes: The Role of Mediterranean Diet Adherence
Grahovac, M., Kumrić, M., Vilović, M., Šupe‐Domić, D., Pavlović, N., Bukić, J., Kurir, T. T., & Božić, J. (2025) · Nutrients · doi:10.3390/nu17152517 · Cited by 5
“…a diagnosis of prediabetes according to the American Diabetes Association’s latest criteria: fasting plasma glucose level between 5.6 and 6.9 mmol/L or hemoglobin A1c level between 5.7% and 6.4% or oral 2 h plasma glucose level during an oral glucose tolerance test between 7.8 and 11.0 mmol/L [21].”
InfluentialNarváez, J. J. U., Guerrero‐Analco, J. A., Monribot‐Villanueva, J. L., Chan‐Zapata, I., & Campos, M. R. S. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106781 · Cited by 3
Craciun, L. M., Buleu, F. N., Iurciuc, S., Popa, D. I., Pop, G. N., Goanta, F., Barbulescu, G. I., Pah, A.-M., Badalica-Petrescu, M., Bodea, O., et al. (2025) · Medicina · doi:10.3390/medicina61081349 · Cited by 5
“Patients with T2DM received their diagnosis before being admitted to the hospital, which aligns with the consensus report from the ADA [16].”
Pregnancy and Birth Trends Across Australia, the United States of America and the United Kingdom
Arthurs, A. L., Harrison, J., Williamson, J. M., & Roberts, C. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165841 · Cited by 4
“There is less uniformity in the USA [28].”
Xie, Z., Luo, X., Ling, D., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01728-z · Cited by 3
Pop‐Busui, R., Petersen, E., Levy, B. L., Tesfaye, S. H., Armstrong, D. G., Grunberger, G., Boulton, A. J. M., Bharara, M., Edgar, D. R., Province‐Azalde, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101647 · Cited by 4
Beyond Accuracy: Assessment of Statistical Imputation Techniques for Heart Rate Data
Gupta, V., & Maleshkova, M. (2025) · BIO Web of Conferences · doi:10.1051/bioconf/202519503002 · Cited by 3
Chacko, S. R., Sharma, S. S., Ahmadian, S., Saini, J., Fell, V. M., Peersen, A. F., Atkinson, E. J., Gruber, L., Gompel, J. J. V., Simha, V., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf693 · Cited by 3
Grotta, R. L., Pellegrini, V., Prattichizzo, F., Amata, O., Panella, L., Frizziero, A., Visconti, M., Averame, G., Brasesco, P. C., Calabrese, I., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041127 · Cited by 2
“Using the criteria of the American Diabetes Association [17], those with FG < 100 mg/dL were considered not at risk and received general counselling on healthy lifestyles; those with FG ≥ 126 mg/dL were considered as possible cases of T2D and were referred to the Diabetes Center for further…”
MethodVirtual insulin pump initiation is safe effective in children adolescents with type 1 diabetes
Nwosu, B. U., Pellizzari, M., Pavlovic, M. N., Ciron, J., Talib, R., & Sohail, R. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1362627 · Cited by 4
Zhang, W., Sun, J., Yu, H., Shi, M., Hu, H., & Yuan, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405517 · Cited by 4
The increase in diabetes in children from underdeveloped countries
Zhang, C., & Luo, X. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001366 · Cited by 3
“Diabetes can be diagnosed by increased or A1C levels, and classified conventionally into syndromes, and drug-induced or chemical-induced diabetes), and gestational diabetes [2].”
BackgroundÇakır, B. T., Aktemur, G., Karabay, G., Şeyhanlı, Z., Sucu, S. T., Eroğlu, Ö. O., Ergani, S. Y., & İskender, C. (2024) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15872 · Cited by 3
Fujihara, K., Matsubayashi, Y., Kitazawa, M., Sato, T., Takeuchi, M., Oura, T., & Sone, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15887 · Cited by 5
Vollmer, J., Christian, W. J., & LACY, M. E. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01717-y · Cited by 5
“By the age of 30 years, ~ 25–30% of women with PCOS will have impaired glucose tolerance [2, 5].”
BackgroundMethodInfluentialZhu, B., Yin, B., Li, H., Chu, X., Mi, Z., Sun, Y., Yuan, X., Chen, R., & Ma, Z. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111865 · Cited by 3
Westcott, F., Nagarajan, S. R., Parry, S. A., Savic, D., Green, C., Marjot, T., Johnson, E. M., Cornfield, T., Mózes, F. E., O’Rourke, P., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae123 · Cited by 6
Self-citationUnraveling the molecular crossroads: T2DM and Parkinson’s disease interactions
Liu, T., KONG, X., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.056272 · Cited by 3
Parajuli, S., Tamburrini, R., Aziz, F., Dodin, B. E., Astor, B. C., Mandelbrot, D. A., Kaufman, D. B., & Odorico, J. S. (2024) · Transplantation Direct · doi:10.1097/txd.0000000000001721 · Cited by 3
Li, Q., Chen, Y., Yang, M., & Li, P. (2024) · BMC Public Health · doi:10.1186/s12889-024-20490-0 · Cited by 5
“Diabetes was characterized by a glycated hemoglobin A1c level of 6.5% or higher, fasting glucose exceeding 7 mmol/L, a 2-hour post 75 g glucose load (OGTT) result of 11.1 mmol/L or more, self-reported diabetes diagnosis, or self-reported usage of insulin or other diabetic treat-ment [22, 24].”
BackgroundInfluentialBullón‐Vela, V., Martínez-Tabar, A., Etxezarreta-Uranga, M., Martínez‐González, M. Á., Basterra-Gortari, F. J., & Bes‐Rastrollo, M. (2024) · Medicina · doi:10.3390/medicina60111881 · Cited by 4
Zeng, Q., Liu, J., Liu, X., Liu, N., Wu, W., Watson, R. G., Zou, D., Wei, Y., & Guo, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1397423 · Cited by 3
Hu, X., Wang, X., Cai, C., Guo, J., Qian, X., Yu, J., Huang, L., & Xie, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1514713 · Cited by 3
Zhao, Y., Liu, D., Pan, X., & Tan, Y. (2024) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.24-00199 · Cited by 3
Conquering diabetes by overcoming psychological barriers and embracing health
Őry, F., Kiss, B. L., Zsido, A. N., & Teleki, S. Á. (2024) · Scientific Reports · doi:10.1038/s41598-024-83837-y · Cited by 6
Husami, S. F., Kaur, T., Gupta, L., Rastogi, G., Singh, L., Meena, P., Sharma, I., Singh, H., & Sharma, V. (2025) · Scientific Reports · doi:10.1038/s41598-024-84160-2 · Cited by 3
Sarcopenia and Cardiovascular Diseases in Individuals With Diabetes or Prediabetes
Wang, X., Zeng, Q., Yu, X., & Li, S. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70024 · Cited by 3
“Diabetes was defined as an FPG ≥ 7.0 mmol/L, HbA1c ≥ 6.5% (48 mmol/mol), a self-reported history of diabetes, and/or the use of anti-diabetic medications [20].”
InfluentialJotić, A., Stoiljkovic, M. M., Milicic, T. J., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01713-y · Cited by 3
“Inclusion criteria were diagnosed EOT2D under the age of 40 years based on the American Diabetes Association diagnostic criteria, with a duration of at least 12 months before pregnancy [11, 12].”
Kopytek, M., Undas, K. W., Tarasiuk, J., Wroński, S., Ząbczyk, M., & Natorska, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02691-y · Cited by 5
“Exclusion criteria were as follows: previously diagnosed type 2 DM [14], chronic kidney disease stages 4 and 5 or dialysis-depen-dent patients, left ventricular ejection fraction (LVEF) of 40%, atherosclerotic vascular disease requiring revascularization, clinically evident coronary artery…”
InfluentialGeraci, G., Sorce, A., Zanoli, L., Calabrese, V., Cuttone, G., Mattina, A., Ferrara, P., Dominguez, L. J., Polosa, R., Mulè, G., et al. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00714-z · Cited by 4
“…mg/dl were classified as diabetics, whereas the diagnosis of diabetes was confirmed in individuals with fasting serum glucose 100–125 mg/dL by both glycated hemoglobin or 2-hour plasma glucose during oral glucose tolerance test, as recommended by the American Diabetes Association guidelines [25].”
Zhou, X., Fu, X., Zhang, Y., Zhou, J., Cui, Y., & Liu, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-02567-x · Cited by 4
“(3) Diabetes was diagnosed on the basis of a hemoglobin A1c level ≥ 6.5%, a fasting plasma glucose value ≥ 126 mg/dL, a 2-hour plasma glucose value ≥ 200 mg/dL during a 75-g oral glucose tolerance test, a random glucose value ≥ 200 mg/dL, or classic hyperglycemic symptoms/crisis criteria 23 .”
InfluentialZeng, J., Chen, C.-H., Tao, Y., Cheng, H., Chen, D., Shen, Z., & Li, H. (2025) · QJM · doi:10.1093/qjmed/hcaf286 · Cited by 3
Population prevalence, penetrance, and mortality for genetically confirmed MODYPreprint
Sharp, L. N., Colclough, K., Leech, J. M., et al. (2025) · medRxiv · doi:10.1101/2025.06.30.25330354 · Cited by 3
AbdulAbbas, A. M., Alkanany, R., Al-Nuaimi, Y. A. K., & Al-Hamdawee, Z. M. A. (2025) · Engineering, Technology & Applied Science Research · doi:10.48084/etasr.14155 · Cited by 3
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu‐Hilal, L. H., & Leon, B. G. C. (2026) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70187 · Cited by 3
Becker, N., Pereyra, D., Dingfelder, J., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144051 · Cited by 2
“Type 1 and type 2 diabetes mellitus were classified using the 2024 ADA guidelines [21].”
MethodMhaibes, S. H., & Ali, S. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.280 · Cited by 2
Sathish, T., Fil, F. E., Prokou, M., Venkatachalam, A., Kumar, S., Shifaly, F., & Oldenburg, B. F. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_67_24 · Cited by 3
Gronroos, N. N., Swift, C., Frazer, M., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., & Noone, J. M. (2024) · Journal of health economics and outcomes research · doi:10.36469/001c.124111 · Cited by 4
Jin, Z., Sun, W., Huang, J., & Wang, G. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1482328 · Cited by 2
Quiñones, S. D. L., Luque‐Ramírez, M., Fernández, A. C. M., Tobar, A. Q., Quiñones‐Silva, J., Martínez-García, M. Á., Insenser, M. R., Avendaño, B. D., Escobar-Morreale, H. F., & Nattero‐Chávez, L. (2025) · Metabolites · doi:10.3390/metabo15010055 · Cited by 2
MRM-based LC-MS method for accurate C-peptide quantitation
Grothoff, W., Khodakivskyi, I., Shin, A., Little, R. R., Connolly, S. M., & Kabytaev, K. (2025) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2025.02.001 · Cited by 3
“As type 1 and type 2 diabetes manifest differences in insulin secretion, C-peptide can aid in distinguishing between diabetes types, helping to avoid misclassification [6,7].”
Asada, Y., Horiguchi, T., Yagi, K., Komatsu, M., Yamashita, A., Ueta, R., Yamaaki, N., Shikida, M., Nishio, S., & Inagaki, M. (2025) · Medicina · doi:10.3390/medicina61020352 · Cited by 2
“…American Diabetes Association and the Japan Diabetes Society: HbA1c levels ≥ 6.5% (National Glyco-haemoglobin Standardisation Programme), fasting blood glucose concentration ≥ 126 mg/dL (7.0 mmol/L), random blood glucose concentration ≥ 200 mg/dL, or current use of medications for diabetes [9,10].”
InfluentialMuntean, M., Mărginean, C., Bernad, E. S., Bănescu, C. V., Nyulas, V., Muntean, I. E., & Săsăran, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041654 · Cited by 3
“T2DM is defined as a value of glycosylated hemoglobin A1c (HbA1c) ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, or 2 h plasma glucose ≥ 126 mg/dL during an oral glucose tolerance test, or a patient with symptoms of hyperglycemia or hyperglycemic crisis and a random glucose ≥ 200 mg/dL [5].”
InfluentialZhu, H., Zhong, Z., Zhao, G., Cao, Y., Liu, W., Guo, Y., & Jin, J. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s511208 · Cited by 2
“24 Diabetes was defined as a fasting blood glucose (FBG) level of ≥7.0 mmol/L, or a 2-hour plasma glucose (2hPG) level of ≥11.1 mmol/L during an oral glucose tolerance test (OGTT), or a glycated hemoglobin (HbA1c) level of ≥6.5%.”
InfluentialPlatelets indices clinical implications in diabetes mellitus: A broader insight
Mirghani, H. O. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.100467 · Cited by 6
Zhang, K., Huang, C., Li, J., Mai, P., Xu, S., Huang, F., He, W., Zhang, H., Liu, Y., & Feng, W. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100952 · Cited by 3
“Diabetes was assessed at each examination according to American Diabetes Association diagnostic criteria for laboratory measures and a history of diabetes medication use [19].”
Xuan, X., Sun, M., Hu, D., & Lu, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1501159 · Cited by 2
Beckmann, S. B., Bhawan, P., Bruning, T., Kuijper, T. M., & Jainandunsing, S. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02513-3 · Cited by 5
“Validated risk scores are endorsed by the American Dia - betes Association (ADA) [10] and other national diabetes organizations, including the Dutch Diabetes Federation [ 11 ], as a screening tool for T2D.”
Polzin, A., Scheiber, D., Voß, F., Haurand, J. M., Zweck, E., Oehler, D., Maier, O., Gastl, M., Spieker, M., Moos, C., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15330 · Cited by 3
Primary aldosteronism in hypertensive patients with obstructive sleep apnea
Hu, Z., & Chen, X. (2025) · Blood Pressure · doi:10.1080/08037051.2025.2507680 · Cited by 2
“In the absence of typical hyperglycaemia symptoms, confirmation required two abnormal test results obtained simultaneously or at separate time points [14].”
Smaller Pancreas Volume in Insulin-Dependent Monogenic Diabetes
Williams, J. M., Hilmes, M. A., Letourneau, L. R., et al. (2025) · Diabetes · doi:10.2337/db25-0318 · Cited by 2
The Association of Diabetes Care & Education Specialists (2025) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106251337489 · Cited by 2
Lin, K., Zhai, C., Ai, W., Lan, Y., Zhao, Y., Zhai, Q., Ge, J., & Yan, Y. (2025) · Translational research · doi:10.1016/j.trsl.2025.05.006 · Cited by 2
Secondulfo, C., Torre, P., Iacuzzo, C., Pietro, R. A. D., Apicella, L., Vecchione, N., Masarone, M., Persico, M., & Bilancio, G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03967-7 · Cited by 3
Late Preterm Antenatal Corticosteroids in Pregestational and Gestational Diabetic Pregnancies
Haizler‐Cohen, L., Alzamora, M. C., Legro, N. R., Eter, L., Freed, T., Rahematpura, S., Arafat, A., Greenberg, V., & Iqbal, S. N. (2025) · American Journal of Perinatology · doi:10.1055/a-2624-8405 · Cited by 2
Ji, J., Qiao, M., Ding, Y., Wei, X., Wan, D., Wu, L., & Liu, H. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s513574 · Cited by 4
Avisar, H., Greenbaum, U., Djaldetti, R., & Lerner, B. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01003-1 · Cited by 3
“The de fi nition of prediabetes or diabetes was based on the current “ Standards of Care in Diabetes ” 49 .”
Genetics Evaluation Outcomes From an Academic Multidisciplinary Atypical Diabetes Program
Chase, C. L., Accardo, M.-L., Greve, V., Ames, E. G., Quinonez, S. C., Scott, A. J., Hipp, L. E., Damon, J., Uhlmann, W. R., Broome, D. T., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf091 · Cited by 2
“Diabetes mellitus is a group of metabolic disorders characterized by hyperglycemia, which is due to defects in insulin secretion, insulin action, or both [1].”
Tekin, S., Öçal, A., Güleroğlu, F. Y., Selcuk, C. G. O., Eyisoy, Ö. G., Ocal, E. U. B., & Çetin, A. (2025) · Journal of Perinatal Medicine · doi:10.1515/jpm-2025-0135 · Cited by 2
Predictors of BMI reduction with phentermine/topiramate in adolescents with obesity
Bensignor, M. O., FREESE, R. L., Rudser, K. D., Kelly, A. S., Kunin‐Batson, A., Gross, A. C., Bramante, C. T., Shih, W., Peterson, C. A., & Fox, C. K. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01821-6 · Cited by 2
“Participants with a fasting glucose level between 100 – 125 mg/dL or 2-h glucose level between 140 – 199 mg/dL were classi fi ed as “ prediabetes ” [12].”
Chen, X.-X., Tao, L., & Wang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01810-9 · Cited by 5
“Next, based on the 2024 American Diabetes Association guidelines [15], participants who did not meet the diagnostic criteria for diabetes or prediabetes were excluded ( n = 19985).”
Trajectories of healthy lifestyle index and prediabetes risk of adult workers in Japan
Kuwahara, K., Yamamoto, S., Honda, T., Nakagawa, T., Konishi, M., & Mizoue, T. (2025) · Communications Medicine · doi:10.1038/s43856-025-00971-y · Cited by 3
“4 ;WorldHealthOrganizationusesahigherfastingplasmaglucose threshold (110 – 125 mg/dL) with the same 2-h post-load plasma glucose range (140 – 199 mg/dL); and the International Expert Committee criteria de fi nesprediabetesasHbA1cof6.”
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.